IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Dennis Ding Dennis Ding Jefferies & Company Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference Read more about Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan Read more about Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C Read more about Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights Read more about Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus Read more about Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting Read more about Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders Read more about Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration Read more about Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption Read more about Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption Pagination First page « First Previous page ‹ Previous … Page 14 Page 15 Page 16 Page 17 Current page 18 Page 19 Page 20 Page 21 Page 22 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference Read more about Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan Read more about Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C Read more about Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights Read more about Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus Read more about Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting Read more about Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders Read more about Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration Read more about Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption Read more about Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption